TABLE 2.
P-Scores for the treatment regimens and outcomes.
| Treatment regimen | P-Score rankinga | ||||||
| All-cause mortality | MACEs | MI | Stroke | Stent thrombosis | Major bleeding | ICH | |
| Rivaroxaban | 0.969 | 0.949 | 0.360 | 0.960 | 0.317 | 0.591 | 0.621 |
| Prasugrel | 0.369 | 0.486 | 0.989 | 0.575 | 0.968 | 0.396 | 0.550 |
| Ticagrelor60 | 0.632 | 0.648 | 0.405 | 0.622 | 0.382 | 0.224 | 0.347 |
| Ticagrelor90 | 0.416 | 0.581 | 0.449 | 0.554 | 0.515 | 0.097 | 0.496 |
| Clopidogrel | 0.210 | 0.130 | 0.730 | 0.065 | 0.541 | 0.694 | 0.187 |
P-Score ranking of efficacy and safety outcomes of various dual anti-thrombotic regimens for chronic coronary syndrome.
aThe P-score represents the probability that each intervention is better than all the competing interventions, as derived from network point estimates and standard errors. MACE, major adverse cardiovascular events; MI, myocardial infarction; ICH, intracerebral hemorrhage.